Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial

This report has been verified by one or more authors of the original publication.

94 postmenopausal osteoporotic women were randomized to receive either 60mg denosumab subcutaneously every 6 months, 20ug teriparatide subcutaneously daily, or a combination treatment of both 60mg denosumab and 20ug teriparatide for a duration of 24 months. The purpose of this study was to compare the individual response rates of the three treatment groups in terms of increases in bone mineral density (BMD) at the total hip, femoral neck, lumbar spine, and distal one-third radius shaft. Outcomes were assessed up to 24-month follow-up. Findings indicated a significantly greater rate of response (>3% increase in BMD from baseline) in the combination therapy group when compared teriparatide monotherapy at the total hip, femoral neck and distal 1/3 raidus sites, as well as compared to denosumab monotherapy at the total hip and femoral neck sites.